Vivante GMP Solutions, Inc. (”Vivante”; www.vivante-gmp.com) today announced that it has successfully completed the fill/finish and lot release testing for Etubics Corporation’s (”Etubics”; www.etubics.com) ETBX-011 adenovirus vector-based gene therapy product for Phase I/II clinical trials. Etubics approached Vivante with an urgent... (Continue reading)
Vivante GMP Solutions, Inc. (”Vivante”; www.vivante-gmp.com) today announced that it has entered into a relationship with Aseptic Technologies (”Aseptic”; www.aseptictech.com) whereby Vivante will offer to its clients filling and finishing capabilities using Aseptic’s cutting-edge filling technology. Aseptic Technologies is a company... (Continue reading)
Vivante GMP Solutions, Inc. (”Vivante”; www.vivante-gmp.com) today announced that it has successfully completed a “QP audit” of its manufacturing facility and quality systems. The audit was performed by a Qualified Person (QP) on behalf of a Vivante client, in anticipation of... (Continue reading)
Vivante GMP Solutions, Inc. (’Vivante’; www.vivante-gmp.com) today announced that it has finalized its license agreements with Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX). Both a patent license and a vendor network manufacturing service license agreement were executed.... (Continue reading)